SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lüders H., Lesser RP., Dinner DS., Morris HH. Benign focal epilepsy of childhood. In: LüdersH., LesserRP. Epilepsy. Elec-troclinical Syndromes. Berlin : Springer; 1987; 30346.
  • 2
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30 38999.
  • 3
    Lerman P. Benign partial epilepsy with centra-temporal spikes. In: RogerJ., BureauM., DravetC., DreifussFE., PerretA., WolfP. Epileptic Syndromes in Infancy, Childhood and Adolescence. 2nd ed. London : John Libbey; 1992; 89200.
  • 4
    Loiseau P., Duche B. Benign rolandic epilepsy. In: ChauvelP., Delgado-EscuetaAV. Advances in Neurology. Vol 57. New York : Raven Press 1992; 4117.
  • 5
    Lerman P., Lerman-Sagie T. Sulthiame revisited. J Child Neurol 1995; 10 2412.
  • 6
    Lerman P. Seizures induced or aggravated by anticonvulsants. Epilepsia 1986; 27 70610.
  • 7
    Fejerman N., Di Blasi AM. Status epilepticus of benign partial epilepsies in children: report of two cases. Epilepsia 1987; 28 3515.
  • 8
    Marescaux C., Hirsch E., Finck S., et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990; 31 76877.
  • 9
    Deonna TW., Roulet E., Fontan D., Marcoz JP. Speech and oromotor deficits of epileptic origin in benign partial epilepsy of childhood with Rolandic spikes. Relationship to the acquired aphasia epilepsy syndrome. Neuropediatrics 1993; 24 834.
  • 10
    Gross-Selbeck G. Treatment of “benign” partial epilepsies of childhood, including atypical forms. Neuropediatrics 1995; 26 4550.
  • 11
    Doose H., Baier WK., Ernst JP., Tuxhorn I., Volzke E. Benign partial epilepsy. Treatment with sulthiame. Dev Med Child Neurol 1988; 30 6834.
  • 12
    Bauer P., Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50 102941.
  • 13
    Wirth W., Hoffmeister F., Friebel H., Sommer S. Zur Pharmakologie des N-(4'-Sulfamylphenyl)-butansuItam-(l-4). Deut Med Wschr 1960; 85 21959.
  • 14
    Hansen JM., Kristensen M., Skovsted L. Sulthiame (Ospolot) as inhibitor of diphenylhydantoin metabolism. Epilepsia 1968; 9 1722.
  • 15
    Green JR., Troupin AS., Halpern LM., Friel P., Kanarek P. Sulthiame: evaluation as an anticonvulsant. Epilepsia 1974; 15 32919.
  • 16
    Raffauf HJ. Die Behandlung zerebraler Anfallsleiden mit Ospolot. Deut Med Wschr 1960; 85 22037.
  • 17
    Doose H., Ehmsen U. Bericht über die Erfahrungen mit Ospolot bei der Behandlung kindlicher Epilepsien an der Universitätskinder Klinik Kiel. In: SelbachH. Internationales Kolloquium iiber das Antikonvulsivum Ospolot. Kamp-Lintfort : Staufen-Verlag; 1963; 189203.
  • 18
    Binnie CD., Marston D. Cognitive correlates of interictal discharges. Epilepsia 1992;33(Suppl 6): S1117.
  • 19
    Wakai S., Ito N., Ueda D., Chiba S. Landau-Kleffner syndrome and sulthiame. Neuropediatrics 1997; 28 1356.
  • 20
    Bourgeois B., Brown LW., Pellock JM., et al. Gabapentin (Neuron-tin) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36-week, double-blind, placebo-controlled study. Epilepsia 1998; 39 (suppl 6): 163.
  • 21
    Browne TR., Ascanape JS. Diones, paraldehyde, phenacemide, bromides, and sulthiame. In: EngelJ., PedleyTA. Epilepsy: A Comprehensive Textbook. Philadelphia : Lippincott-Raven Publishers; 1997; 162744.
  • 22
    Ahrend KF., Nagy L., Tiess D. Zur Morphologie und Analytik der Sultiamum-Intoxikation. Arch Toxikol 1969; 25 22937.
  • 23
    Report of the ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998; 39 799803.